论文部分内容阅读
目的对派罗欣联合利巴韦林在慢性丙型病毒性肝炎(丙肝)治疗中的临床疗效和可靠性进行探讨。方法 86例慢性丙肝患者,随机分成观察组和对照组,各43例。观察组以派罗欣联合利巴韦林进行治疗,对照组以干扰素联合利巴韦林进行治疗。治疗1年后,对两组患者的治疗效果和不良反应进行评估对比。结果观察组总应答率高于对照组,不良反应发生率低于对照组,差异均具有统计学意义(P<0.05)。结论派罗欣与利巴韦林合并治疗慢性丙肝患者的疗效非常显著,不但安全、有效,还有利于患者预后质量的明显改善,值得在临床治疗中大力推广。
Objective To investigate the clinical efficacy and reliability of Pegasys combined with ribavirin in the treatment of chronic hepatitis C (hepatitis C). Methods 86 cases of chronic hepatitis C patients were randomly divided into observation group and control group, 43 cases in each. The observation group was treated with Pegasys and ribavirin, while the control group was treated with interferon plus ribavirin. After 1 year of treatment, the efficacy and adverse reactions of both groups were evaluated and compared. Results The total response rate of the observation group was higher than that of the control group, and the incidence of adverse reactions was lower than that of the control group (P <0.05). Conclusion The efficacy of combination of PEGASYS and ribavirin in the treatment of chronic hepatitis C patients is very significant. It is not only safe and effective, but also significantly improves the quality of prognosis of patients. It is worth promoting in clinical treatment.